UK markets open in 1 hour 7 minutes

e-Therapeutics plc (ETX.L)

LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
9.18+0.32 (+3.67%)
At close: 04:21PM BST

e-Therapeutics plc

4 Kingdom Street
Floor 4 Unit 4B Paddington Central
London W2 6BD
United Kingdom
44 20 4551 8888
https://www.etherapeutics.co.uk

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 34

Key executives

NameTitlePayExercisedYear born
Mr. Ahmad Ali MortazaviCEO & Director270kN/A1971
Mr. Timothy BrethertonCFO, Director of Finance & Operations and Company SecretaryN/AN/AN/A
Dr. Laura Roca-Alonso Ph.D.Chief Operating & Business OfficerN/AN/AN/A
Mr. Alan Whitmore B.Sc., Ph.D.Chief Scientific OfficerN/AN/AN/A
Mr. Ankit SharmaHead of Software EngineeringN/AN/AN/A
Mr. Graham CraggsHead of Therapeutic DiscoveryN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.

Description

e-therapeutics plc engages in drug discovery research activities in the United Kingdom. It offers HepNet, a proprietary, hepatocyte-specific, and computational biology platform that addresses key limitations of the biopharmaceutical industry, including extracting value from big data, addressing complex diseases, and improving translatability in research and development; and GalOmic, a RNA interference (RNAi) chemistry platform, which enables the generation of GalNAc-conjugated short interfering RNA drug candidates for hepatocyte-specific gene silencing through RNAi of any target gene identified by HepNet. The company was incorporated in 2001 and is based in London, the United Kingdom.

Corporate governance

e-Therapeutics plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.